Trial Profile
A Randomized, Double-Blind, Placebo Controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 853 in Subjects With Inadequately Controlled Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs AMG-853 (Primary)
- Indications Asthma
- Focus Biomarker; Therapeutic Use
- Sponsors Amgen
- 06 Mar 2012 Results presented at the 68th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 19 May 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 29 Apr 2011 Status changed from active, no longer recruiting to discontinued (development of drug discontinued).